Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $225.00 short call and a strike $230.00 long call offers a potential 38.89% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $225.00 by expiration. The full premium credit of $1.40 would be kept by the premium seller. The risk of $3.60 would be incurred if the stock rose above the $230.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Key Developments for Allergan in 2Q17
Wed, 23 Aug 2017 13:07:03 +0000
Allergan (AGN) is a leading pharmaceuticals company involved with pharmaceuticals, over-the-counter products, eye care, and aesthetics products.
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
Wed, 23 Aug 2017 12:31:12 +0000
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
Allergan Teams Up With Comedian Vanessa Bayer and OB/GYN Jessica Shepherd, M.D., M.B.A, to Debut the Know Your Birth Control Campaign
Wed, 23 Aug 2017 12:30:00 +0000
“We are committed to women's health and believe it is important to provide a resource about birth control in a fresh and approachable way to address the misinformation that still exists,” said Jim Maffezzoli, Vice President, Women's Healthcare, Allergan.
How Allergan’s International Segment Performed in 2Q17
Wed, 23 Aug 2017 11:37:09 +0000
Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.
ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan, Inc. – (AGN)
Wed, 23 Aug 2017 02:50:00 +0000
NEW ORLEANS, Aug. 22, 2017– ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 29, 2017 to file lead plaintiff applications in a securities class action …
Related Posts
Also on Market Tamer…
Follow Us on Facebook